Targovax ASA ( (GB:0RIS) ) has issued an announcement.
Circio Holding ASA has announced advancements in its circVec 3.0 RNA therapeutic platform, demonstrating efficient delivery to the spleen, which opens new opportunities in cell therapy. The company has also strengthened its financial position through a rights issue and private placement, enabling continued R&D progress and positioning itself for potential partnerships.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing circular RNA vector expression technology for next-generation nucleic acid medicine. The company has established a unique circRNA platform for DNA, RNA, and viral therapeutics, offering enhanced and durable protein expression compared to traditional mRNA systems. Circio is also developing a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.
YTD Price Performance: -93.95%
Average Trading Volume: 23,211
Technical Sentiment Signal: Buy
Current Market Cap: NOK43.27M
For detailed information about 0RIS stock, go to TipRanks’ Stock Analysis page.